Similarly, Liu et al. identified RUNX1 as an oncogenic contributor to pancreatic cancer growth, indicating its potential as both a prognostic biomarker and therapeutic target 12, supported by elevated RUNX1 RNA levels in cancerous compared to normal pancreatic tissues 50. This evidence concerns the gene RUNX1 and pancreatic neoplasm.